Thymosin alpha-1 has minimal effect on tumor cells but strongly activates CD8+ T cells for anti-cancer immunity | Research

The takeaway

Thymosin alpha-1 showed minimal transcriptional immunomodulation on melanoma, glioblastoma, and mesothelioma cells but significantly affected immune cell subsets, with the greatest impact on activated CD8+ T cells crucial for anti-tumor immunity.

CD8+ T cells most responsive
Thymosin alpha-1 had its greatest transcriptional impact on activated CD8+ T cells while barely affecting tumor cell immunogenicity

What the researchers found

Cancer cells: minimal DEGs and immune-related changes after Tα1. Immune cells: significant transcriptional changes in all subsets. Greatest impact: activated CD8+ T cells. Tα1 directly affects immune cell proliferation and transcription.

Why it matters

Understanding that Tα1 works through immune activation rather than direct tumor modification is crucial for designing combination immunotherapy strategies—Tα1 should be paired with approaches that enhance tumor antigen presentation.

How the study worked

nCounter SPRINT Profiler gene expression analysis of melanoma, glioblastoma, mesothelioma cell lines and HD CD4+ T, CD8+ T, B, NK cells after 48h Tα1 treatment.

What this study cannot tell us

In vitro only. Gene expression may not reflect protein-level changes. Healthy donor immune cells may respond differently than cancer patient cells. Limited cancer types tested.

How to read the evidence

In vitro transcriptomic study with appropriate controls. Good mechanistic insight but limited to gene expression.

When this study was published

Published in 2025.

The bigger picture

This clarifies Tα1's role as an immune enhancer rather than a direct tumor modifier, guiding rational combination with checkpoint inhibitors, vaccines, or other immunotherapies.

Questions still open

Should Tα1 be combined with checkpoint inhibitors for optimal anti-tumor immunity?
Does Tα1 activate tumor-infiltrating CD8+ T cells as effectively as peripheral ones?
Would patient-derived immune cells show the same Tα1 response?

Common questions

Does thymosin alpha-1 directly fight cancer?

Not really. This study found Tα1 has minimal direct effects on cancer cells themselves. Instead, it powerfully activates immune cells—especially CD8+ T cells that kill cancer. This means Tα1's anti-cancer value is through boosting the immune system, not directly attacking tumors.

How should thymosin alpha-1 be used in cancer treatment?

Based on these findings, Tα1 should be combined with treatments that help the immune system recognize cancer cells (like vaccines or checkpoint inhibitors), since its main strength is supercharging immune cell activity rather than making tumors more visible to the immune system.

Read the original research

The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets.

OncoTargets and therapy, 18, 995-1012

View on PubMed ↗Publisher’s paper ↗

Citation

Solmonese, Laura; Lofiego, Maria Fortunata; Fazio, Carolina; Marzani, Francesco; Piazzini, Francesca; Bello, Emma; Celesti, Fabrizio; Giacobini, Gianluca; Wang, Xiaohui; Maio, Michele; Coral, Sandra; Di Giacomo, Anna Maria; Covre, Alessia. (2025). The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets.. OncoTargets and therapy, 18, 995-1012. https://doi.org/10.2147/OTT.S527785